Replies to post #864 on Zynerba Pharmaceuticals (ZYNE)

[midas716]

I'm guessing the analysts are clueless.

Analyst Actions: Piper Jaffray Upgrades Zynerba Pharmaceuticals to Overweight from Neutral

07:08 AM EDT, 09/29/2017 (MT Newswires) -- Zynerba Pharmaceuticals'(ZYNE) average rating among analysts is a hold, with an average price target of $11.

Price: 9.95, Change: +0.51, Percent Change: +5.40

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.